Encapsulation of Single or Multiple Molecules in Nano- and Microparticles for Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 6090

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Herbal Medicine Resource, Kangwon National University, 346 Hwangjo-gil, Dogye-eup, Samcheok-si 25949, Gangwon-do, Republic of Korea
2. Department of Biopharmaceutical Engineering, 1 Gangwondaehak-gil, Seoksa-dong, Chuncheon-si 24341, Gangwon-do, Republic of Korea
Interests: controlled release; bioavailability; lipid-based nanoparticles; transdermal delivery; oral delivery; polymeric particulate system
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the last few decades, there have been extensive efforts to develop novel systems for the encapsulation of active molecules in nano- and microparticulate systems. The particulate systems are designed to deliver encapsulated active molecules to a specific site for achieving improved therapeutic effects and reduced adverse effects.

Recently, many patients are suffering from chronic diseases and tend to take multiple pills to manage the diseases. In view of this, an encapsulation of multiple drugs in a single carrier has been developed to provide better patient compliance as well as therapeutic effects. Since an encapsulation of single or multiple molecules in delivery systems is affected by diverse factors, numerous studies have been conducted to establish the optimization of the preparation procedures.

The aim of this Special Issue is to gather current research progress and outputs in nano- and microparticles for drug delivery purposes. Articles that describe physicochemical properties, release profiles, in vitro cellular studies, and in vivo animal works are welcome.

Dr. Jong-Suep Baek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • encapsulation
  • multiple drugs
  • nanoparticles
  • microparticles
  • controlled release

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2861 KiB  
Article
Intranasal Cerium Oxide Nanoparticles Ameliorate Cognitive Function in Rats with Alzheimer’s via Anti-Oxidative Pathway
by Syed Mohammad Danish, Anshul Gupta, Urooj Ahmad Khan, Nazeer Hasan, Farhan Jalees Ahmad, Musarrat Husain Warsi, Ahmed M. Abdelhaleem Ali, Ameeduzzafar Zafar and Gaurav Kumar Jain
Pharmaceutics 2022, 14(4), 756; https://doi.org/10.3390/pharmaceutics14040756 - 30 Mar 2022
Cited by 16 | Viewed by 2429
Abstract
Cerium oxide nanoparticles (CNPs), owing to their antioxidant property, have recently emerged as therapeutic candidate for Alzheimer’s disease (AD). However, intravenous CNPs are limited due to their poor physicochemical properties, rapid blood clearance and poor blood–brain penetration. Thus, we developed intranasal CNPs and [...] Read more.
Cerium oxide nanoparticles (CNPs), owing to their antioxidant property, have recently emerged as therapeutic candidate for Alzheimer’s disease (AD). However, intravenous CNPs are limited due to their poor physicochemical properties, rapid blood clearance and poor blood–brain penetration. Thus, we developed intranasal CNPs and evaluated its potential in experimental AD. CNPs were synthesized using homogenous precipitation method and optimized through Box–Behnken Design. The formation of CNPs was confirmed by UV spectroscopy and FTIR. The optimized CNP were spherical, small (134.0 ± 3.35 nm), uniform (PDI, 0.158 ± 0.0019) and stable (ZP, −21.8 ± 4.94 mV). The presence of Ce in CNPs was confirmed by energy-dispersive X-ray analysis. Further, the X-ray diffraction spectra revealed that the CNPs were nano-crystalline. The DPPH assay showed that at concentration of 50 µg/mL, the percentage radical scavenging was 95.40 ± 0.006%. Results of the in vivo behavioral studies in the scopolamine-induced Alzheimer rat model showed that intranasal CNPs dose dependently reversed cognitive ability. At dose of 6 mg/kg the morris water maze results (escape latency, path length and dwell time) and passive avoidance results (retention latency) were significantly different from untreated group but not significantly different from positive control group (rivastigmine patch, 13.3 mg/24 h). Further, biochemical estimation showed that intranasal CNP upregulated the levels of SOD and GSH in brain. In conclusion, intranasal CNPs, through its antioxidant effect, could be a prospective therapeutics for the treatment of cognitive impairment in AD. Full article
Show Figures

Figure 1

17 pages, 3567 KiB  
Article
Orally Administered Natural Lipid Nanoparticle-Loaded 6-Shogaol Shapes the Anti-Inflammatory Microbiota and Metabolome
by Chunhua Yang, Dingpei Long, Junsik Sung, Zahra Alghoul and Didier Merlin
Pharmaceutics 2021, 13(9), 1355; https://doi.org/10.3390/pharmaceutics13091355 - 28 Aug 2021
Cited by 12 | Viewed by 2981
Abstract
The past decade has seen increasing interest in microbiota-targeting therapeutic strategies that aim to modulate the gut microbiota’s composition and/or function to treat chronic diseases, such as inflammatory bowel disease (IBD), metabolic symptoms, and obesity. While targeting the gut microbiota is an innovative [...] Read more.
The past decade has seen increasing interest in microbiota-targeting therapeutic strategies that aim to modulate the gut microbiota’s composition and/or function to treat chronic diseases, such as inflammatory bowel disease (IBD), metabolic symptoms, and obesity. While targeting the gut microbiota is an innovative means for treating IBD, it typically requires an extended treatment time, hampering its potential application. Herein, using an established natural-lipid nanoparticle (nLNP) platform, we demonstrate that nLNPs encapsulated with the drug candidate 6-shogaol (6S/nLNP) distinctly altered microbiota composition within one day of treatment, significantly accelerating a process that usually requires five days using free 6-shogaol (6S). In addition, the change in the composition of the microbiota induced by five-day treatment with 6S/nLNP was maintained for at least 15 days (from day five to day 20). The consequent alteration in the fecal metabolic profile stemming from this compositional change manifested as functional changes that enhanced the in vitro anti-inflammatory and wound-healing efficacy of macrophage cells (Raw 264.7) and epithelial cells (Caco-2 BBE1), respectively. Further, this metabolic compositional change, as reflected in an altered metabolic profile, promoted a robust anti-inflammatory effect in a DSS-induced mouse model of acute colitis. Our study demonstrates that, by near-instantly modulating microbiota composition and function, an nLNP-based drug-delivery platform might be a powerful tool for treating ulcerative colitis. Full article
Show Figures

Figure 1

Back to TopTop